BioStock: Magle Group on Q2: ”We saw a perfect storm of one-time effects”
Last Friday, Magle Group published its Q2 report, which showed results below market expectations, impacted by delays in high-value customer orders and raw material shortages. At the same time, the company continues to invest in its core areas – DSM, biopolymers, and stem cell technologies. BioStock invited Aaron Wong, CFO of Magle Group, to the studio to comment on the quarter.
See the interview with Aaron Wong here biostock.se:
https://biostock.se/en/2025/08/magle-group-on-q2-we-saw-a-perfect-storm-of-one-time-effects/